Coya Therapeutics announces this morning the issuance of a U.S. patent relevant to its investigational ready-to-use liquid formulation of IL-2, strengthening its strategic and business development optionality. Read more in our latest press release: ir.coyatherapeutics.com/news/news-deta…

Coya Therapeutics CEO Arun Swaminathan recently joined Bryce McNallie on the McNallie Money Podcast to discuss the latest with the company and the progress being made on our therapeutics. Thanks for having us! youtu.be/IKdQqWEgPys #CoyaTherapeutics $COYA

Coya's Daniel Barvin recently joined others at the Seattle Mariners and MLB in celebration of Lou Gehrig Day to raise awareness about the fight to #EndALS. Coya is pioneering research into the function of #Tregs to target #neurodegenerative diseases like #ALS. Learn more at the Lou

#ICYMI, Our CEO Arun Swaminathan recently presented at the H.C. Wainwright & Co. Annual BioConnect Investor Conference in May about the latest with the Company and our therapeutics. You can listen to the full presentation by following this link to the webcast: bit.ly/4jzqQeh $COYA

CEO Arun Swaminathan was featured this morning in PharmaVoice discussing important candidates that could shake up the #ALS treatment landscape, including COYA 302. Coya Therapeutics is focused on enhancing the power of Tregs to better treat #neurodegenerative diseases. Read

Living with #ALS is challenging and current treatments only offer limited slowing, not a cure. Patients need and deserve a better quality of life. Coya Therapeutics is researching the power of #Tregs for #neurodegenerative diseases like ALS. Learn more from The ALS Association:

Coya Therapeutics is proud to announce our new Vice President of Clinical Development Mark Gordon! A board-certified neurologist and fellowship-trained specialist in Movement Disorders, he brings extensive experience across academic, clinical, research, and industry settings to

Team Coya will be in Dallas on August 11-14 attending #ALSNexus hosted by the The ALS Association. We look forward to engaging in stimulating discussions and networking with leaders changing the future of #ALS! Send us a note at [email protected] if you would like to connect!

Coya Therapeutics announced 2Q25 financial results and provides a corporate update. Read more in our latest press release: prnewswire.com/news-releases/… $COYA

We are on the ground at #ALSNexus! This event brings together researchers, advocates, industry leaders, and people living with #ALS, all working towards changing the future of ALS. At Coya, we're proud to contribute to this mission and look forward to collaborating, learning,

We are thrilled to share that our very own Daniel Barvin, VP of Operations and Patient Advocacy, has been honored with the ALS Hero Award at this year’s #ALSNexus! This award recognizes individuals making a profound impact on the ALS community, and Daniel does just that every

Listen to this exciting discussion on the Business of Biotech podcast with our CEO, Arun Swaminathan, alongside Milan Kalawadia from Dr. Reddy’s Laboratories Ltd, where they discuss our company’s partnership to develop our lead asset COYA 302, a novel dual-mechanism immunotherapy for the treatment

Coya Therapeutics has announced that the FDA has accepted its Investigational New Drug (IND) application for COYA 302’s Phase 2 Trial in #ALS. This milestone marks a critical step forward as we advance our mission of delivering hope and new options to those living with ALS. $COYA

Our CMO Dr. Fred Grossman joined Solomon Wilcots to discuss the significance of the FDA’s approval of our IND application for our Phase 2 study evaluating the efficacy and safety of COYA 302 in patients with #ALS, as well as our Treg-based approach to treatment for ALS. At Coya,

We’re excited to share that the FDA has cleared our IND application for COYA 302 in ALS, paving the way for our upcoming Phase 2 trial. This milestone also activates a $4.2M payment from our partner, Dr. Reddy’s Laboratories Ltd. This marks a major step forward in our mission to develop innovative